Abstract:BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00082?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00082</a>.Synthesis of compounds 17a–e, crystal data for compound 29, SFC report for compounds 3a and 3b, and the determination of the absolute configuration of compound (S)-23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_002.csv">CSV</a>)X-ray crystal structure data for compound 29 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00082/suppl_file/jm1c00082_si_003.cif">CIF</a>)This article has not yet been cited by other publications.

Design, Synthesis, and Biological Evaluation of Novel Water-Soluble Triptolide Derivatives: Antineoplastic Activity Against Imatinib-Resistant CML Cells Bearing T315I Mutant Bcr-Abl

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Design, Synthesis, and Biological Evaluation of Novel Bcr-AblT315I Inhibitors Incorporating Amino Acids As Flexible Linker

Design, Synthesis, and Biological Evaluation of Trizole-Based Heteroaromatic Derivatives As Bcr-Abl Kinase Inhibitors.

Bcr-Abl Inhibitory Activities of Imatinib Derivatives

Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib

Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents.

Synthesis and Biological Evaluation of Novel Aromatic-Heterocyclic Biphenyls As Potent Anti-Leukemia Agents

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Design, Synthesis, Cytotoxic Activity and Molecular Docking Studies of New 20(S)-Sulfonylamidine Camptothecin Derivatives

In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach

Discovery of a Candidate Containing an ( S )-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H -inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

Design, Synthesis, and Biological Evaluation of Cyclobentinib (CB1107) As a Potential Anti-Cml Agent

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6h-pyrimido[5,4-b][1,4]oxazin-7(8h)-one Derivatives As A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.

Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors

Design, in silico Evaluation, and Determination of Antitumor Activity of Potential Inhibitors Against Protein Kinases: Application to BCR-ABL Tyrosine Kinase